SCHEMBL7141597

SCHEMBL7141597

CCOC(=O)c1ccc(NC(=O)CN(C)C(=O)C2CC(S)CN2S(=O)(=O)CCCc2ccccc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.45
GAA P10253 3/20 0.45
MME P08473 1/20 0.45
ACE P12821 1/20 0.45
ECE1 P42892 1/20 0.45
LMNA P02545 1/20 0.43
CA12 O43570 1/20 0.42
CA9 Q16790 1/20 0.42
ALDH1A1 P00352 5/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ALOX12 P18054 1/20 0.41
MAPK1 P28482 5/20 0.40
TP53 P04637 1/20 0.40
TSHR P16473 1/20 0.39
NAMPT P43490 1/20 0.39
ABL1 P00519 1/20 0.39
RIN1 Q13671 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7152599 1.00 MAPT (0.45) MAPTGAAMMEACEECE1
SCHEMBL7136104 0.95 MAPT (0.46) MAPTGAAMMEACEECE1
SCHEMBL7150285 0.95 MAPT (0.46) MAPTGAAMMEACEECE1
SCHEMBL7141907 0.91 MAPT (0.52) MAPTGAAMMEACEECE1
SCHEMBL7148177 0.91 MAPT (0.52) MAPTGAAMMEACEECE1
SCHEMBL7150121 0.89 MME (0.46) MAPTGAAMMEACEECE1
SCHEMBL7152592 0.86 MAPT (0.44) MAPTGAALMNACA12CA9
SCHEMBL7138193 0.86 MME (0.46) MAPTMMEACEECE1LMNA
SCHEMBL7150476 0.86 MME (0.46) MAPTMMEACEECE1LMNA
SCHEMBL7144390 0.83 MME (0.46) MAPTGAAMMEACEECE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303485-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed
WO-2002006222-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP MAPT 2428/4885GAA 130/4885MME 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.